Ron Rosenstraus
@Eversept Partners, Lp
Latest period2024 - Q3ReportedManaged Assets$1.46BTotal holdings67
Assets growth rate-0.03%Assets growth rate (2-Q avg)-1.3%Continuous growth in asset value0 quarters
Portfolio positions
This chart displays the top 10 holdings in Eversept Partners, Lp's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 67 positions.
Assets under management
The assets under management (AUM) of Eversept Partners, Lp over the past 10 years (40 quarters) show continuous growth in total asset value over the last 0 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 1.46B in assets, with a quarterly growth rate of -0.03% and a 2-quarter average growth rate of -1.3%. The portfolio is managed by Ron Rosenstraus, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
NVONovo-nordisk A S
| 0% | $20.976M 146,956 shares@ $142.74 avg price | Exited |
LLYEli Lilly & Co
| 0% | $19.224M 21,233 shares@ $905.39 avg price | Exited |
ARGXArgenx Se
| 0% | $14.876M 34,593 shares@ $430.05 avg price | Exited |
XBISpdr Ser Tr
| 0% | $9.271M 100,000 shares@ $92.71 avg price | Exited |
VKTXViking Therapeutics Inc
| 0% | $7.341M 138,489 shares@ $53.02 avg price | Exited |
PCVXVaxcyte Inc
| 0% | $7.256M 96,089 shares@ $75.51 avg price | Exited |
CYTKCytokinetics Inc
| 0% | $6.874M 126,877 shares@ $54.19 avg price | Exited |
OSCROscar Health Inc
| 0% | $4.918M 310,893 shares@ $15.82 avg price | Exited |
CERECerevel Therapeutics Hldng I
| 0% | $4.498M 110,010 shares@ $40.9 avg price | Exited |
MYGNMyriad Genetics Inc
| 0% | $4.451M 181,961 shares@ $24.46 avg price | Exited |